Gujarat Themis Biosyn Q4 FY26: Growth Holds, While Acquisitions Reset the Scale

In Q4 FY26, income from operations was Rs 44.23 crore, EBITDA was Rs 19.36 crore (43.77% margin), and PAT was Rs 10.89 crore (24.62% margin). EPS was Rs 1.00.

FY26 income from operations was Rs 165.82 crore versus Rs 150.80 crore in FY25. FY26 EBITDA was Rs 75.53 crore versus Rs 68.84 crore, while PAT was Rs 46.68 crore versus Rs 48.77 crore.

GTBL disclosed an asset purchase agreement to acquire a portfolio of 13 brands from Sanofi, France, focused on TB and anti-infectives. It is structured as an asset acquisition of brands, marketing authorizations, dossiers and inventory with no manufacturing capex or employee transfer.

GTBL disclosed a definitive agreement to acquire 100% of MicroBiopharm Japan Co., Ltd. for JPY 21.5 billion (about INR 1,300 crore), funded through a mix of debt and equity. The transaction is expected to close in Q2 FY2027, subject to regulatory approvals including FEFTA in Japan.

The presentation highlights Rifamycin S (intermediate for Rifampicin) and Rifamycin O (intermediate for Rifaximin) as current products.

GTBL is setting up a hybrid wind plus solar power plant in Gujarat for captive consumption. The presentation states a capacity of about 18 MW and highlights benefits including lower power costs, reduced grid reliance and improved ESG profile.

The presentation reports RoCE at 14.5% in FY26 (down from 57.9% in FY22), RoA at 9% in FY26 (down from 36% in FY22), and RoE at 16.2% in FY26 (down from 42.2% in FY22).